Urodynamix Technologies is focused on the development of non-invasive diagnostic products based on its proprietary near-infrared spectroscopy (NIRS) platform technology. 

Clinical applications include:

• Lower urinary tract symptoms (LUTS)
• Prostate cancer and benign prostatic hyperplasia (BPH)
• Erectile dysfunction (ED)
• Intra-abdominal hypertension and abdominal compartment syndrome (ACS)

Lower Urinary Tract Symptoms (LUTS)

Urodynamix's NIRS Bladder Monitor System is designed to provide a catheter-free product for integration with existing hospital and office-based urodynamics (UDS®) equipment that is faster, cheaper, and easier to use than existing UDS equipment.

• The World Health Organization estimates that UI affects over 200 million people worldwide.

• UI affects 20% of people over 40 and 40% of people over 60 with annual financial costs of $26 billion in the US.

• Up to 50% of patients who require urodynamic testing decline due to embarrassment and fear of catheterization.

* UDS® is a registered trademark of Laborie Medical Technologies.

Prostate Cancer (PCa) Imaging

Urodynamix's NIRS DRE technology is designed to provide the world's first office-based digital rectal exam (DRE) imaging system to measure blood flow in the prostate gland and aid in the screening, diagnosis and treatment of prostate cancer.

• Vast market with 150 million men in the US, Europe and Japan qualify for annual prostate cancer screening.

• Prostate cancer is the most commonly diagnosed non-skin cancer in North America with 250,000 new cases and 30,000 deaths per year.

• Prostate cancer treatment and biopsies cost $10 billion per year in the US.

Erectile Dysfunction (ED)

Urodynamix's NIRS ED technology is designed to provide a non-invasive office based device to aid in the diagnosis of the underlying etiology of ED, in patients who have failed prior treatment, providing additional information that is not currently available.

• Over 30 million American men experience chronic ED, 85% of whom suffer from a physical condition.

• An estimated 20% of men affected by ED, or 3 to 5 million men in the United States alone, do not respond to medical treatment with oral PDE5 inhibitors and require further study to resolve the condition

• Within 20 years, 322 million men worldwide will be affected by ED.

Abdominal Compartment Syndrome (ACS)

Urodynamix's NIRS Intra-Abdominal Pressure (IAP) Monitor is designed to provide the world’s first non-invasive continuous monitoring technology of IAP for integration with existing patient monitoring equipment, to reduce costs, improve morbidity and mortality in patients with intra-abdominal hypertension or abdominal compartment syndrome.

• 5 million adult patients are treated in 60,000 ICU beds each year with direct annual costs of over US$55 billion.

• Approximatley 50% of trauma ICU patients develop sustained, elevated intra-abdominal pressure (IAP) and up to 10% of patients with elevated IAP progress to ACS, which is fatal if not promptly diagnosed.

• Despite improved recognition and treatment options, the overall mortality rate of ACS remains over 50%.